Sanjivani Paranteral Ltd - Stock Valuation and Financial Performance

BSE: 531569 | NSE: | Pharmaceuticals & Drugs | Small Cap

Sanjivani Paranteral Share Price

272.20 12.95 5.00%
as on 21-Feb'25 16:59

DeciZen - make an informed investing decision on Sanjivani Paranteral

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Sanjivani Paranteral stock performance -

P/E Ratio (SA):
45.13
Market Cap:
323.4 Cr.
52-wk low:
122.2
52-wk high:
397

Is Sanjivani Paranteral Ltd an attractive stock to invest in?

1. Is Sanjivani Paranteral Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sanjivani Paranteral Ltd is a average quality company.

2. Is Sanjivani Paranteral Ltd undervalued or overvalued?

The key valuation ratios of Sanjivani Paranteral Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Sanjivani Paranteral Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sanjivani Paranteral Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Sanjivani Paranteral:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sanjivani Paranteral Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE %
5.7%-7.3%-33%-227.3%0%-266%266.4%0%0%55.3%-
Value Creation
Index
-0.6-1.5NANANANA18.0NANA3.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales
13311532.71825.116.425.130.635.554.465
Sales YoY Gr.
--13.2%-71.7%-45%39.7%-34.8%53.4%22%15.9%53.3%-
Adj EPS
-4.2-25.2-46-90-3.7-3.21.54.74.256
YoY Gr.
-NANANANANANA214.8%-10.9%20.3%-
BVPS (₹)
54.529.7-14.8-89.6-80-82.9-52.8-7.6-3.122.130.7
Adj Net
Profit
-2.5-14.9-27.2-53.1-2.2-1.91.34.74.25.97
Cash Flow from Ops.
-1.20.59.63.12.5-0.20.68.54.7-10.7-
Debt/CF from Ops.
-47.6139.76.315.819.4-280.1790.70.5-0.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -9.5%16.7%29.4%53.3%
Adj EPS NANA50%20.3%
BVPS-9.5%NANANA
Share Price 31.8% 99.1% 67.8% 60.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
-7.4-60-618.2172.54.43.9-2.7-17.9-78.447.322.8
Op. Profit
Mgn %
4-4.8-70.4-289.8-7-3.48.513.914.814.715.3
Net Profit
Mgn %
-1.9-12.9-83.1-295.5-8.7-11.35.115.311.810.811.1
Debt to
Equity
1.83.6-6.9-0.9-1-1-1-0.8-0.80-
Working Cap
Days
26328472264917117913312812111893
Cash Conv.
Cycle
197221567420-105-169-112-90-82-357

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 22.80%

Sales growth is growing at healthy rate in last 3 years 29.42%

Net Profit is growing at healthy rate in last 3 years 50.01%

Sales growth is good in last 4 quarters at 33.63%

No data to display

Latest Financials - Sanjivani Paranteral Ltd.

Standalone Consolidated
TTM EPS (₹) 6 -
TTM Sales (₹ Cr.) 64.8 -
BVPS (₹.) 30.7 -
Reserves (₹ Cr.) 25 -
P/BV 8.87 -
PE 45.13 -
From the Market
52 Week Low / High (₹) 122.15 / 396.95
All Time Low / High (₹) 1.76 / 396.95
Market Cap (₹ Cr.) 323
Equity (₹ Cr.) 11.9
Face Value (₹) 10
Industry PE 37.5

Quarterly Results

 Mar'24 YoY Gr. Rt. %Jun'24 YoY Gr. Rt. %Sep'24 YoY Gr. Rt. %Dec'24 YoY Gr. Rt. %
Sales (₹ Cr.) 141 33.4154 35.7168 30.9182 32.9
Adj EPS (₹) 2.7 205.61.6 19.71.9 -8.92.2 67.7
Op. Profit Mgn % 5.12 224 bps4.24 -46 bps4.32 53 bps4.46 46 bps
Net Profit Mgn % 1.95 110 bps2.16 -30 bps2.35 -102 bps2.48 52 bps

Management X-Ray of Sanjivani Paranteral:

Shareholding Pattern

JavaScript chart by amCharts 3.21.5
JavaScript chart by amCharts 3.21.5Promoters:27.67%Institutions:6.25%Non-Institutions:66.08%

Promoter's Holding & Share Pledging

JavaScript chart by amCharts 3.21.5Sep22Dec22Mar23Jun23Sep23Dec23Mar24Jun24Sep24Dec240%5%10%15%20%25%30%35%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Sanjivani Paranteral

MRP
spaceLock icon
MOS
spaceLock icon%
DP
spaceLock icon
Base EPS
spaceLock icon
DPS
spaceLock icon
MRP: ₹ 0
DP: ₹0
Base EPS ₹:
DPS ₹:
MOS (%):
Expected EPS Growth Rate:
0%
Base 0%
50%
Expected Rate of Return:
0%
Base 0%
50%
Future PE:
0
Base 0
200
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max

Event Update

Login/Register to view analysis.

Analyst's Notes

No data found!

Key Ratios of Sanjivani Paranteral

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Company Name CMP(₹)
Change ₹(%)
Market Cap
Net Sales (₹ Cr.)
Latest EPS (₹)
Net Profit Margin %
Latest P/E
Latest P/BV
Alembic Pharma 802.8 -10.6 (-1.3%) Small Cap 6,229 30.8 9.6 26.4 3.2
Laurus Labs 521.1 -15.4 (-2.9%) Small Cap 5,041 3.7 3.1 144.5 6.9
Piramal Pharma 208.6 -9.5 (-4.3%) Small Cap 4,390 5.2 8.4 42.1 4.1
Ajanta Pharma 2,607.3 -63.1 (-2.4%) Small Cap 4,209 71.9 19 37.2 8.5
Gland Pharma 1,524.3 3.9 (0.3%) Small Cap 4,167 68.1 24.8 22.3 2.7
Natco Pharma 797.8 4.8 (0.6%) Small Cap 3,999 104.1 34.5 7.6 2
Granules India 509 -18.4 (-3.5%) Small Cap 3,755 13.3 11.7 39.7 3.9
Emcure Pharma 996.8 5.2 (0.5%) Small Cap 3,498 8.5 4.4 116.8 6.5
JB Chem & Pharma 1,605.5 -25 (-1.5%) Small Cap 3,299 40.4 16.1 40.4 7.7
Sanofi India 5,076.8 -91.3 (-1.8%) Small Cap 2,851 184.4 20.8 28 15.5
Shows rows:

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales1331153318251625313554
Operating Expenses 1281215670271723263046
Manufacturing Costs1222112334
Material Costs120113282515915121928
Employee Cost 3333222334
Other Costs 3423408448510
Operating Profit 5-6-23-52-2-12458
Operating Profit Margin (%) 4.0%-4.8%-71.2%-290.0%-7.0%-3.4%8.5%13.9%14.8%14.7%
Other Income 1130100211
Interest 8950010000
Depreciation 1111111111
Exceptional Items 0000000000
Profit Before Tax -3-15-26-53-2-21558
Tax 0000000001
Profit After Tax -2-15-26-53-2-21556
PAT Margin (%) -1.8%-12.7%-80.3%-295.0%-8.2%-10.4%5.7%15.8%12.7%11.3%
Adjusted EPS (₹)-4.1-24.8-44.5-90.0-3.5-2.91.74.94.55.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 3218-9-53-47-49-45-8-326
Share Capital 6666668101012
Reserves 2612-15-59-53-55-53-18-1314
Minority Interest0000000000
Debt55615745454542311
Long Term Debt51274885311
Short Term Debt50495041373737000
Trade Payables12631212111111146
Others Liabilities 1498218912121011
Total Liabilities 114936025181619182143

Fixed Assets

Gross Block22222222222222232427
Accumulated Depreciation891112131414151617
Net Fixed Assets141311109887810
CWIP 0000000000
Investments 0000000000
Inventories23201021212510
Trade Receivables6748325517525
Cash Equivalents 10000000010
Others Assets101277354469
Total Assets 114936025181619182143

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity -1010320195-11
PBT -3-15-17-53-2-21558
Adjustment 8962121-111
Changes in Working Capital -76215530-24-1-18
Tax Paid 000000000-1
Cash Flow From Investing Activity 9-100000-1-1-12
Capex 9-100000-1-1-3
Net Investments 000000000-9
Others 0000000000
Cash Flow From Financing Activity -7-1-10-3-200-8-423
Net Proceeds from Shares 00000032025
Net Proceeds from Borrowing -18-5-3410000
Interest Paid -8-8-500-10000
Dividend Paid 0000000000
Others 1000-60-3-9-3-2
Net Cash Flow 0-100000000
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)-7.19-58.98N/AN/AN/AN/AN/AN/AN/A54.08
ROCE (%)5.69-7.28N/AN/AN/AN/AN/AN/AN/A55.32
Asset Turnover Ratio1.151.120.430.421.170.971.471.661.811.77
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/A11.81-1.83
Working Capital Days
Receivable Days181182446378767055683521
Inventory Days6068168124212518163648
Payable Days473060108289461264327247125

Sanjivani Paranteral Ltd Stock News

Sanjivani Paranteral Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Sanjivani Paranteral on 21-Feb-2025 16:59 is ₹272.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Feb-2025 16:59 the market cap of Sanjivani Paranteral stood at ₹323.4.
The latest P/E ratio of Sanjivani Paranteral as of 21-Feb-2025 16:59 is 45.13.
The latest P/B ratio of Sanjivani Paranteral as of 21-Feb-2025 16:59 is 8.87.
The 52-week high of Sanjivani Paranteral is ₹396.9 and the 52-week low is ₹122.2.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sanjivani Paranteral is ₹64.78 ( Cr.) .

About Sanjivani Paranteral Ltd

Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company’s products includes oral solids, small volume parenterals and sterile powder formulations.

The company has grown many folds and aspires to be a respected research-based company. With its diverse product portfolio, it is rapidly expanding its reach to the global marketplace, riding on its success in India and in the world’s emerging and developed markets.

After establishing itself in India, Sanjivani has extended its reach globally by entering the markets of Asia, Europe, Africa and Latin America.  The company has active presence in countries like Russia, Ukraine, Uzbekistan, Turkmenistan, Fiji, Vietnam, Sri Lanka, Nepal, Malaysia, Thailand, Nigeria and Peru, to name a few.  Sanjivani Parenteral has also got its plant approved by the registration authorities of Congo, Sudan and Sri Lanka. It is making its presence felt in the world market now, through leveraging its manufacturing capacity, quality of products and international alliances.

International business contributes about 30% of the company’s revenue and is set to grow to more than 50% in the coming two years. This includes the sales of Sanjivani’s own brands and the revenue from the contract manufacturing services that the company provides to its overseas clients. The company is in the making of a strong base to broaden its horizons. 

Sanjivani has been a regular supplier to the armed forces’ hospitals in India. Furthermore, many government and private hospitals have availed of the products and services offered by Sanjivani across the country.  The company also has its own marketing operations in India and boasts of over 1000 distributors all over India.

Products

  • Therapeutic Products
  • Animal Products
  • Key Products
  • Oral Solids
Read More Read Less
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on